Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM8002 + pemetrexed
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**PM8002 + pemetrexed** is a combination investigational cancer therapy currently in clinical trials. PM8002 is a bispecific monoclonal antibody that targets PD-L1 (programmed death ligand 1) and VEGF (vascular endothelial growth factor), thereby potentially boosting immune responses against cancer and inhibiting angiogenesis[3][9]. Pemetrexed is a folate antimetabolite chemotherapy agent that inhibits enzymes involved in purine/pyrimidine synthesis required for DNA and RNA replication, thereby impairing cancer cell growth and survival[2][7][10]. This combination is under investigation for use as a first-line treatment, especially for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM)[1][3][5][9].
- Brand names
- AlimtaPemfexyPemrydi RTUAXTLE
- Other names
- PM8002 + pemetrexedArmisartePemetrexed AccordPemetrexed Fresenius Kabi
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)GART (GAR transformylase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)
Beyond the preview
Go deeper on PM8002 + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM8002 + pemetrexed.